Oral vs. Intravenous Proton-Pump Inhibitors for Bleeding Peptic Ulcers

Oral PPIs are as effective as IV PPIs in preventing rebleeding after successful endoscopic therapy.

High-dose intravenous (IV) proton-pump inhibitor (PPI) therapy decreases rebleeding in patients with nonvariceal gastrointestinal bleeding (NVGIB) and high-risk endoscopic stigmata (HRS). Some studies have shown a similar effect with oral PPI treatment.

To compare the effectiveness of these two therapeutic approaches, investigators performed a systematic review and meta-analysis of seven randomized trials involving 859 patients with NVGIB and HRS who received oral or IV PPI treatment after successful endoscopic therapy.

The pooled relative risk for rebleeding within 30 days was similar with oral or IV PPI therapy (risk ratio, 0.90); rebleeding rates were also similar with either therapy at 3, 7, and 15 days after endoscopy. Mortality, length …

Reviewing Author

David J. Bjorkman, MD, MSPH (HSA), SM (Epid.)

Disclosures

Nothing to disclose

David J. Bjorkman, MD, MSPH (HSA), SM (Epid.)

Disclosures

Nothing to disclose

Oral vs. Intravenous Proton-Pump Inhibitors for Bleeding Peptic Ulcers

Topics

Reviewing Author